An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations - Université Paris-Est-Créteil-Val-de-Marne Access content directly
Journal Articles Advances in Therapy Year : 2023

An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Lise Bosquet
Nicolas Girard
Anna Kron
Frank Griesinger
Santiago Viteri
Craig Knott
Bernardo Rodrigues
  • Function : Author
Nora Rahhali
Janka Mielke
  • Function : Author
Tracy Li
  • Function : Author
Parthiv Mahadevia
  • Function : Author
Jürgen Wolf

Abstract

Introduction: Patients with advanced, epidermal growth factor receptor (EGFR)-mutated, non-small cell lung cancer (NSCLC) with Exon 20 insertion mutations (Exon20ins) have poor prognoses, exacerbated by a previous lack of specific treatment guidelines and unmet need for targeted therapies. Amivantamab, an EGFR and MET bispecific antibody, demonstrated efficacy and tolerability in patients with advanced EGFR-mutated NSCLC with Exo-n20ins following platinum-based therapy in CHRYSALIS (NCT02609776; Cohort D?). Since CHRYSALIS was single-arm, individual patient
Fichier principal
Vignette du fichier
12325_2022_Article_2408.pdf (870.19 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

hal-04141252 , version 1 (26-06-2023)

Identifiers

Cite

Christos Chouaid, Lise Bosquet, Nicolas Girard, Anna Kron, Matthias Scheffler, et al.. An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations. Advances in Therapy, 2023, 40 (3), pp.1187-1203. ⟨10.1007/s12325-022-02408-7⟩. ⟨hal-04141252⟩
22 View
22 Download

Altmetric

Share

Gmail Facebook X LinkedIn More